North Star Investment Management’s Esperion Therapeutics ESPR Stock Holding History

North Star Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Hold	45,000	–	–	0.01%	553
2026 Q1	$123K	Hold	45,000	–	–	0.01%	570
2025 Q4	$167K	Buy	45,000 +10,000	+29%	+$32.3K	0.01%	469
2025 Q3	$92.8K	Buy	35,000 +10,000	+40%	+$19.3K	0.01%	540
2025 Q2	$24.6K	Buy	+25,000	New	+$25K	﹤0.01%	753
2021 Q4	–	Sell	-100	Closed	-$1K	–	1194
2021 Q3	$1K	Hold	100	–	–	﹤0.01%	1071
2021 Q2	$2K	Hold	100	–	–	﹤0.01%	1015
2021 Q1	$3K	Hold	100	–	–	﹤0.01%	946
2020 Q4	$3K	Hold	100	–	–	﹤0.01%	916
2020 Q3	$4K	Hold	100	–	–	﹤0.01%	874
2020 Q2	$5K	Hold	100	–	–	﹤0.01%	821
2020 Q1	$3K	Buy	+100	New	+$5.28K	﹤0.01%	882
2019 Q2	–	Sell	-70	Closed	-$3K	–	552
2019 Q1	$3K	Hold	70	–	–	﹤0.01%	973
2018 Q4	$3K	Hold	70	–	–	﹤0.01%	962
2018 Q3	$3K	Hold	70	–	–	﹤0.01%	988
2018 Q2	$3K	Hold	70	–	–	﹤0.01%	1001
2018 Q1	$5K	Hold	70	–	–	﹤0.01%	936
2017 Q4	$5K	Buy	+70	New	+$3.77K	﹤0.01%	912

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

North Star Investment Management's ESPR Position: Q2 2026 in Review

North Star Investment Management held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 45,000 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #553.

North Star Investment Management first reported a position in ESPR in Q4 2017 and has held it in 18 quarters since. The position peaked at $167K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

North Star Investment Management held 45,000 shares of Esperion Therapeutics worth $142K as of Q2 2026.
North Star Investment Management left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up 0.01% of North Star Investment Management's portfolio in Q2 2026, its #553 holding.
North Star Investment Management first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 18 quarters since.
North Star Investment Management's Esperion Therapeutics position peaked at $167K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.